Alnylam pharmaceuticals reports q1 2020 financial results

Alnylam pharmaceuticals reports first quarter 2020 financial results and highlights recent period activity.sees fy 2020 revenue up 5 percent.lowers 2020 guidance range for onpattro revenue from $285-$315 million to $270-$300 million due to covid-19 pandemic.alnylam pharmaceuticals - cash, cash equivalents, marketable debt and equity securities, and restricted investments were $1.37 billion at end of q1 2020.sees fy 2020 gaap research and development and sg&a expenses of $1,155 million - $1,250 million.qtrly loss per share of $1.62.q1 earnings per share view $-1.89 -- refinitiv ibes data.
ALNY Ratings Summary
ALNY Quant Ranking